This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcasts3D Body AtlasLet’s connectLet's connectContact usSign up

Menu

Close

OverviewStarting Strong in 1LAbout LORVIQUA®Study Design1L study design2L+ study designEfficacy1L overall efficacy1L CNS efficacy1L 5-Year overall efficacy1L 5-Year CNS efficacy2L+ efficacySafetyPooled Safety: all lines1L safety2L+ safetyDosing & Therapy ManagementOnce-daily dosingARs of clinical interestTherapy managementResourcesMaterialsVideos
Prescribing Information 
After 5 years, 1L LORVIQUA® continues to protect against CNS progression1*Unplanned follow up-analysisAt 5 years, 92% of LORVIQUA® - treated patients remained free of CNS progression (INV-assessed, N=296)1

Time to IC progression: ITT population1

Data cutoff: 31 October 20231

  • No new CNS progression events were observed between years 3 and 51
At 5 years, LORVIQUA® protected against CNS progression in patients without baseline brain metastases (INV- assessed, N=223)1

Time to IC progression: ITT population1

    Data cutoff: 31 October 2023.1

    • 96% of patients without baseline brain metastases were protected against CNS progression1
    At 5 years, LORVIQUA® protected against CNS progression in patients with baseline brain metastases (INV- assessed, N=73)1
    • 83% of patients with baseline brain metastases were protected against CNS progression1
    At 5 years, LORVIQUA® demonstrated durable intracranial response rates in patients with brain metastases (INV-assessed, N=296)1,*
      *LIMITATIONS: The results of this unplanned, investigator- assessed analysis are descriptive. No formal hypothesis testing was performed given that the PFS endpoint was previously met in the CROWN trial primary analysis; results are presented descriptively. 1
      †The primary endpoint of PFS was met in the CROWN trial primary analysis (median follow-up for PFS; 18.3 months for patients receiving LORVIQUA® and 14.8 months for patients receiving crizotinib); median PFS was not estimable for the LORVIQUA® arm. An unplanned follow-up analysis was performed at a median follow-up for PFS of approximately 60 months for patients on LORVIQUA® (55 months for patients on crizotinib) to confirm the effect of LORVIQUA® relative to crizotinib with longer follow up.      1L = first-line; 2L= second- line; BICR=blinded independent central review; CNS=central nervous system; HR=hazard ratio; IC-DoR=intracranial duration of response; IC-ORR=intracranial objective response rate; ITT=intention to treat; RECIST=Response Evaluation Criteria in Solid Tumours.      References:Solomon BJ, Liu G, Felip E, et al. Lorlatinib versus crizotinib in patients with advanced ALK- positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. J Clin Oncol 42, 3400-3409 (2024) doi:10.1200/JCO.24.00581.Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018-2029.      Efficacy
      LORVIQUA® safety profile
       Review the safety Loading
      PP-LOR-IRL-0167 | JUL2025

      Adverse events should be reported.

      If you wish to make a medical information inquiry or report an adverse event please contact Pfizer on 1800 633 363 
      or email Pfizer at [email protected] or visit www.PfizerMedicalInformation.ie

      Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

      PfizerPro AccountPfizerPro Account

      Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

      Sign in or RegisterRegisterAccountLog out

      This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

       

      This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.Registered in the Republic of Ireland No. 127002. Directors: M. Adamson (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.

       

      Copyright © 2025 Pfizer Limited. All rights reserved.

      PP-UNP-IRL-0937. July 2025
      For Healthcare Professionals in the Republic of Ireland *

      The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

      I confirm that I am a healthcare professional* resident in the Republic of Ireland.

      If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.

      *The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

      Terms of use

      PP-UNP-IRL-0901. July 2025

      Yes No
      You are now leaving PfizerPro
      You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


      PP-UNP-IRL-0901. July 2025